Compare AbCellera Biologics Inc (ABCL) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

IDRV trades at $38.51, up 2.01% today, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The ETF faces industry headwinds as rising fuel prices boost EV demand globally while US market adoption lags. Recent news highlights competitive threats from Chinese EV makers expanding internationally and regulatory uncertainty around US-China trade policies.

The ETF's outlook is challenged by sector volatility and geopolitical risks, though global EV adoption trends provide long-term growth potential. Key risks include tariff policy changes and slower-than-expected US EV adoption. Investors should monitor quarterly flows and sector performance for directional cues amid mixed technical signals.